CA-DEXCOM
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona. The expanded portfolio includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, a range of exceptionally accurate,* real-time CGM systems designed to empower more people living with diabetes than ever before.
“For two decades, Dexcom has tirelessly innovated to provide the most accurate, connected and accessible CGM technology to people with diabetes around the globe,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Diabetes is not a one-size-fits-all condition—people deserve choice in how they manage their disease. We are excited to be able to provide three gold standard CGM systems that meet the differing needs of people with diabetes.”
Each system in the portfolio offers a different set of features and functionality for various needs across diabetes management; however, all three Dexcom systems eliminate burdensome scanning and painful fingerpricks† for calibration and diabetes treatment decisions.
The Dexcom Real-Time CGM Portfolio
System |
Dexcom G7
1
|
Dexcom G6
|
Dexcom ONE
|
Sensor |
|
|
|
Alerts |
|
|
|
Connectivity |
|
|
|
“Innovation, accuracy and reliability have always been at the core of our work to provide the diabetes community with the best technology possible,” said Chad Patterson, executive vice president of global marketing and product management at Dexcom. “It’s our priority to offer as many people access to the highest standard of care and this portfolio of real-time CGM systems delivers on that commitment.”
In addition to the introduction of Dexcom’s expanded product portfolio, key posters and research presented at ATTD continue to affirm the use of Dexcom CGM is central to optimal diabetes management. Some of these educational presentations may make claims exceeding those cleared by FDA for the labeling of these devices.
Dexcom CGM Accuracy, Performance and Feature Engagement:
- Presentation: “Elevating the standard of care in continuous glucose monitoring with Dexcom CGM.” Moderated by Partha Kar on Thursday, April 28, 2022, 15:00 – 16:30 CET in Hall 116. Speakers include: Žydrūnė Visockienė, MD, PhD; Nicholas Argento, MD, FACE; Lori Laffel, MD, MPH; Hood Thabit, MB, BCh, MRCP, MD, PhD; and Lalantha Leelarathna, MBBS, MRCP, MSc, PhD.
- Presentation: “Dexcom G6 real-time CGM use across the globe: Feature engagement and correlational outcomes.” Moderated by Keri Leone, MS, RD, CDCES on Friday, April 29, 2022, 09:00 – 10:00 CET in Hall 112. Speakers include: Giada Acciaroli, PhD; Robert Dowd, data scientist; Joost van der Linden, PhD; and Anand Iyer, PhD, MBA.
Dexcom Connectivity and Closed Loop Systems:
- Abstract: “Perioperative closed-loop insulin delivery versus standard insulin therapy: A randomised controlled parallel clinical trial in adults with Type 2 diabetes” (David Herzig).
- Abstract: “Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with Type 1 diabetes: a multicentre, multinational, randomised, crossover study” (Charlotte Boughton).
- Abstract: “Performance of Omnipod® 5 Automated Insulin Delivery System at specific glucose targets from 110-150mg/dL over three months in very young children with Type 1 diabetes” (Sarah MacLeish).
- Abstract: “Improvement in HbA1C after 8 weeks of Omnipod 5® Automated Insulin Delivery System use in adults with Type 2 diabetes: From injections to hybrid closed-loop therapy” (Anne Peters).
- Abstract: “A comparison of two hybrid closed-loop systems in Italian children and adults with Type 1 diabetes” (Marina Francesca).
- Abstract: “Glycemic outcomes by age and previous insulin delivery method in Control-IQ technology users: 9 months of CLIO study data” (Jordan Pinsker).
Health Outcomes, Economic Outcomes and Market Access:
- Presentation: “Dexcom G6 real-time CGM use in non-traditional clinical arenas: Hospital and pregnancy.” Moderated by Daniel Chernavvsky, MD on Saturday, April 30, 2022, 08:00 – 08:50 CET in Hall 112. Speakers include: Eileen Faulds, PhD, MS, RN, FNP-BC, CDCES and Anku Mehta, MD.
- Abstract: “The impact of real-time continuous glucose monitoring on treatment satisfaction in adults with Type 2 diabetes: Further findings from the MOBILE randomized clinical trial.” (David Price)
- Abstract: “Association between change in HbA1c and professional CGM use in adults with Type 2 diabetes on non-insulin therapies – a real-world evidence study” (Poorva Nemlekar).
- Abstract: “Reduction in diabetes-related hospitalization rates after real-time continuous glucose monitor (rtCGM) initiation” (Katia Hannah).
- Abstract: “Analysis of alert frequency and glycemic outcomes associated with expanding the default G6 high/low alert range” (Sarah Pickus).
- Abstract: “Cost-effectiveness of a real-time continuous glucose monitoring system versus self-monitoring of blood glucose in Type 2 diabetes patients on insulin in the United Kingdom” (Stephane Roze).
For more information about the 15th International Conference on Advanced Technologies and Treatments for Diabetes and to register to virtually attend the conference, visit https://attd.kenes.com/registration/ .
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com .
*Dexcom G6, Dexcom G7, and Dexcom ONE User Guides. To obtain the Instructions for use for these products, click here . Note that labeling may differ in different countries. |
† If your glucose alerts and readings from Dexcom ONE, Dexcom G6 or Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. |
‡ To view a list of compatible smart devices, visit dexcom.com/compatibility |
†† Separate Follow App required. |
‡‡ Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible |
1 510(k) pending. Not available for sale in the United States. |
© 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6, Dexcom G7 and Dexcom Clarity are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425006053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 11:13:00 CEST | Press release
SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag
Andersen Consulting samarbejder med Mercurial Minds om at forbedre mulighederne inden for digital transformation4.7.2025 01:10:00 CEST | Pressemeddelelse
Andersen Consulting udvider sit udbud af teknologidrevne løsninger med tilføjelsen af samarbejdsfirmaet Mercurial Minds (M.M.), et konsulentfirma inden for digital transformation, AI og IT med base i Pakistan. M.M. blev grundlagt i 2013 og tilbyder en række tjenester, der er designet til at hjælpe organisationer med at udvikle sig og skalere, herunder i forbindelse med deres digitale transformationsstrategi, AI-tjenester, it-rådgivning og udvikling af robuste mobil- og webbrugeroplevelser. Firmaet leverer end-to-end-løsninger – udformning af datadrevne køreplaner, udvikling af intelligent automatisering og levering af sikre mobil- og weboplevelser, der kan skaleres – skræddersyet til virksomheder, der ønsker at forbedre sine forbindelsesmulighederne og opnå indsigter i realtid. M.M. betjener en bred vifte af brancher med fokus på finans, telekommunikation og andre dataintensive sektorer. "Dette samarbejde er en katalysator," siger Nabeel Saiyer, administrerende direktør for M.M. "Vores
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 01:00:00 CEST | Press release
The World Economic Forum report, in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, predicts a significant uptick in tourist trips across the globeThe tourism sector will contribute $16 trillion to global GDP (more than 11% of the global economy) by 2034, according to World Travel & Tourism Council estimates (WTTC)India and China will be responsible for more than 25% of all outbound travel by 2030 The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster th
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 21:00:00 CEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 14:59:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom